MENS
Jyong Biotech Ltd.
NASDAQ · Healthcare · Biotechnology · TW
$1.93
+4.89%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +100.0%
- Operating cash flow
- +100.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -34.5%
- EBIT
- -26.8%
- Net income
- -54.7%
- EPS
- -61.2%
- Free cash flow
- +16.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025